IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Three Months Ended December 31, 2015 and 2014

(Unaudited - Prepared by Management)

Corporate Head Office
Suite 600, 890 West Pender St.
Vancouver, BC V6C 1L9

NOTICE

In accordance with National Instrument 51-102 Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of these interim condensed consolidated financial statements they must be accompanied by a notice indicating that the interim condensed consolidated financial statements have not been reviewed by an auditor.

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management.

IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Unaudited - Prepared by Management)

	December 31, 2015	September 30, 2015
	$	$
ASSETS		
Current assets		
Cash (Note 3)	152,367	29,494
Receivables and prepaids (Notes 4 & 6)	49,983	5,151
Security deposits	5,750	5,750
	208,099	40,395
Equipment (Note 5)	1,019	1,102
Exploration and evaluation assets (Notes 6 and 9)	1	1
	209,119	41,498
LIABILITIES & SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (Notes 7 & 8)	357,560	217,488
Shareholders' equity		
Share capital (Notes 9 & 12)	25,527,873	25,527,873
Shares subscribed (not issued) (Note 9)	149,433	
Share-based payment reserve (Note 9e)	3,919,385	3,919,385
Deficit	(29,745,132)	(29,623,248)
	(148,441)	(175,990)
	209,119	41,498

Nature and continuance operations (Note 1)
Basis of presentation (Note 2)

Approved on behalf of the Board of Directors:

"*Bill Galine*", Director

"*Steve Chan*", Director

See notes to condensed consolidated financial statements

IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

For the Three Months Ended December 31

(Unaudited - Prepared by Management)

	Three Months Ended December 31, 2015 $	Three Months Ended December 31, 2014 $
General and administrative expenses:		
Bank charges and interest	217	287
Consulting fees	37,467	-
Corporate and administration fees	3,220	3,598
Directors' fees	3,000	3,000
Filing and transfer agent fees	8,997	2,143
Legal & accounting fees (Note 8)	55,621	22,325
Management fees (Note 8)	19,500	54,582
Office, rent and insurance	5,719	11,701
Property storage fees	-	546
Shareholders' communication, & promotion	4,460	2,809
Travel, meals & entertainment	1,281	5,195
	(139,482)	(106,186)
Other items:		
Amortization	(83)	(118)
Interest income	8	589
Foreign exchange	(42)	(195)
Other income (expenses recovered)	17,715	-
Net loss and comprehensive loss	(121,884)	(105,910)
Basic and diluted loss per share	(0.03)	(0.3)
Weighted average – number of shares outstanding	3,889,113	3,889,113

See notes to condensed consolidated financial statements

IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three Months Ended December 31

(Unaudited - Prepared by Management)

	2015	2014
	$	$
Cash provided by (used for):		
Operating activities		
Net loss for the period	(121,884)	(105,910)
Adjustments which do not affect cash:		
Amortization	83	118
	(121,801)	(105,792)
Net changes in non-cash working capital items:		
Amounts receivable and prepaids	(44,831)	(8,625)
Accounts payable and accrued liabilities	140,072	29,484
	(26,560)	(84,516)
Financing activities		
Subscriptions received	149,433	-
	149,433	-
Increase (Decrease) in cash	122,873	(84,516)
Cash - beginning of period	29,494	272,376
Cash - end of period	152,367	187,860
Supplementary disclosures:		
Interest income received	8	589
Note 10 – Non-cash transactions		

See notes to condensed consolidated financial statements

IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(Unaudited - Prepared by Management)

	Issued Share Capital		**Share-Based Payment Reserve**	**Subscription Received**	**Deficit**	
	Number of Shares #	**Amount** $	**Share-Based Payment Reserve**	**Subscription Received**	**Deficit**	**Total**
Balance, September 30, 2014	3,889,113	25,527,873	3,919,385	-	(29,220,491)	226,767
Loss for the period	-	-	-	-	(105,910)	(105,910)
Balance, December 31, 2014	3,889,113	25,527,873	3,912,909	-	(29,326,401)	120,857
Loss for the period	-	-	-	-	(296,847)	(296,847)
Balance, September 30, 2015	3,889,113	25,527,873	3,919,385	-	(29,623,248)	(175,990)
Subscriptions received	-	-	-	149,433	-	149,433
Loss for the period	-	-	-	-	(121,884)	(121,884)
Balance, December 31, 2015	3,889,113	25,527,873	3,919,385	149,433	(29,745,132)	(148,441)

See notes to condensed consolidated financial statements

IMAGIN MEDICAL INC.
(Formerly Expedition Mining Inc.)

CONDENSED CONSOLIDATED STATEMENTS OF EXPLORATION AND EVALUATION ASSETS

For the Three Months Ended December 31, 2015

(Unaudited - Prepared by Management)

	Balance October 1, 2014 $	Additions $	Write-off/ Write-down $	Balance September 30, 2015 $	Additions $	Write-off/ Write-down $	Balance December 31, 2015 $
Mt. Mervyn Property (Yukon)							
Acquisition costs	1	-	-	1	-	-	1
Exploration costs:							
Camp	-	-	-	-	-	-	-
Consulting - geology	-	-	-	-	-	-	-
Data acquisition	-	-	-	-	-	-	-
Fieldwork & supplies	-	-	-	-	-	-	-
Geochem and geophysics	-	-	-	-	-	-	-
Helicopter	-	-	-	-	-	-	-
Legal	-	-	-	-	-	-	-
Mobilization	-	-	-	-	-	-	-
Soil sampling, trenching & assays	-	-	-	-	-	-	-
	1	**-**	**-**	**1**	**-**	**-**	**1**

See notes to condensed consolidated financial statements

1. NATURE AND CONTINUANCE OF OPERATIONS

The Company is incorporated in the Province of British Columbia and the principal business activity was the acquisition and exploration of resource properties. On February 9, 2016, the Company completed the acquisition of BSS Life Sciences Inc. ("BSS"). BSS is a private Vancouver-based company that holds the intellectual property rights to a proprietary imaging technology developed for extremely accurate visualization of cancers. Please refer to Note 12 – Subsequent Events. In connection with the acquisition, the Company changed its name to Imagin Medical Inc. The Company will now focus on its new principal business, which is to research, develop and commercialize medical devices in the bio-chemistry industry.

These consolidated financial statements have been prepared assuming the Company will continue on a going-concern basis. The Company has incurred losses since inception and has an accumulated operating deficit of $29,745,132 at December 31, 2015 ($29,623,248 at September 30, 2015). The ability of the Company to continue as a going-concern depends upon its capacity in the near-term to raise additional equity financing and ultimately to develop profitable commercial operations.

There can be no assurance that the Company will be able to continue to raise funds in the future in which case the Company may be unable to meet its obligations. Should the Company be unable to realize on its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded on the statement of financial position.

These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company's consolidated financial statements, including comparatives, have been prepared in accordance with and using accounting policies in full compliance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the IFRS Interpretations Committee.

The policies applied in these consolidated financial statements are based on IFRS issued and outstanding as of February 12, 2016, the date the Board of Directors approved the consolidated financial statements.

These consolidated financial statements are presented in the Company's reporting currency on a historical cost basis.

Statement of compliance to International Financial Reporting Standards

The interim financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). Therefore, these financial statements comply with International Accounting Standard ("IAS") 34 "interim Financial Reporting".

This interim financial report does not include all of the information required of a full annual financial report and is intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Company for the year ended September 30, 2015.

2. SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Financial instruments

(i) Financial assets

The Company classifies its financial assets into one of the following categories, depending on the purpose for which the asset was acquired. The Company's accounting policy for each category is as follows:

Fair value through profit or loss - This category comprises derivatives, or assets acquired or incurred principally for the purpose of selling or repurchasing it in the near term. They are carried in the statement of financial position at fair value with changes in fair value recognized through profit or loss.

Loans and receivables - These assets are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are carried at cost less any provision for impairment. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default.

Held-to-maturity investments - These assets are non-derivative financial assets with fixed or determinable payments and fixed maturities that the Company's management has the positive intention and ability to hold to maturity. These assets are measured at amortized cost using the effective interest method. If there is objective evidence that the investment is impaired, determined by reference to external credit ratings and other relevant indicators, the financial asset is measured at the present value of estimated future cash flows. Any changes to the carrying amount of the investment, including impairment losses, are recognized in the statement of loss and comprehensive loss.
Available-for-sale - Non-derivative financial assets not included in the above categories are classified as available for-sale. They are carried at fair value with changes in fair value recognized directly in equity. Where a decline in the fair value of an available-for-sale financial asset constitutes objective evidence of impairment, the amount of the loss is removed from equity and recognized through profit or loss.

All financial assets except for those at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets, which are described above.

The Company has classified its cash and cash equivalents, security deposits and reclamation bond at fair value through profit and loss. The Company’s accounts receivable are classified as loans and receivables.

(ii) Financial liabilities

The Company classifies its financial liabilities in the following categories:

Other financial liabilities - Other financial liabilities are non-derivatives and are recognized initially at fair value, net of transaction costs incurred and are subsequently stated at amortized cost. Any difference between the amounts originally received, net of transaction costs, and the redemption value is recognized in profit or loss over the period to maturity using the effective interest method.

Other financial liabilities are classified as current or non-current based on their maturity date. Financial liabilities include accounts payable and accrued liabilities.

2. **SIGNIFICANT ACCOUNTING POLICIES** *(continued)*

(ii) Financial liabilities *(continued)*

Derivative financial liabilities - Derivative financial liabilities are initially recognized at their fair value on the date the derivative contract is entered into and are subsequently re-measured at their fair value at each reporting period with changes in the fair value recognized in profit or loss. Derivative financial liabilities include warrants issued by the Company denominated in a currency other than the Company's functional currency.

Principles of consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Expedition Mining USA Inc. All significant inter-company transactions and balances have been eliminated.

Equipment

Equipment is carried at cost, less accumulated amortization and accumulated impairment losses.

Cost comprises the fair value of consideration given to acquire or construct an asset and includes the direct charges associated with bringing the asset to the location and condition necessary for putting it into use, along with the future cost of dismantling and removing the asset.

When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of equipment.

The cost of major overhauls of parts of equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.

Equipment is amortized using the declining-balance method at a rate of 20% per annum for office equipment and 30% per annum for computer equipment.

Foreign currency translation

The reporting currency of the Company is the Canadian dollar.

The functional currency of each of the parent Company and its subsidiary is measured using the currency of the primary economic environment in which that entity operates. The consolidated financial statements are presented in Canadian dollars which is the parent company's functional and presentation currency. The functional currency of the subsidiary is the Canadian dollar.

Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.

Exchange differences arising on the translation of monetary items or on settlement of monetary items are recognized in profit or loss in the statement of loss and comprehensive loss in the period in which they arise.

2. SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Foreign currency translation *(continued)*

Exchange differences arising on the translation of non-monetary items are recognized in other comprehensive income in the statement of loss and comprehensive loss to the extent that gains and losses arising on those non-monetary items are also recognized in other comprehensive income. Where the non-monetary gain or loss is recognized in profit or loss, the exchange component is also recognized in profit or loss.

Exploration and evaluation assets

Once a license to explore an area has been secured, expenditures on exploration and evaluation activities are capitalized to exploration and evaluation assets.

Exploration expenditures relate to the initial search for deposits with economic potential and to detailed assessments of deposits or other projects that have been identified as having economic potential.

Management reviews the carrying value of capitalized exploration costs at least annually. In the case of undeveloped projects, there may be only inferred resources to form a basis for the impairment review. The review is based on a status report regarding the Company's intentions for development of the undeveloped property. In some cases, the undeveloped properties are regarded as successors to ore bodies currently in production. Where this is the case, it is intended that these will be developed and go into production when the current source of minerals is exhausted or to replace the reduced output.

Once an economically viable reserve has been determined for an area and the decision to proceed with development has been approved, exploration and evaluation assets attributable to that area are first tested for impairment and then reclassified to construction in progress within property, plant and equipment.

Subsequent recovery of the resulting carrying value depends on successful development or sale of the undeveloped project. If put into production, the costs of acquisition and exploration will be amortized over the life of the property, based on estimated economic reserves. If a project does not prove viable, all irrecoverable costs associated with the project net of any impairment provisions are written off.

Decommissioning provision

The Company records a liability based on the best estimate of costs for site closure and reclamation activities that the Company is legally or constructively required to remediate and the liability is recognized at the time environmental disturbance occurs. The resulting costs are capitalized to the corresponding asset. The provision for closure and reclamation liabilities is estimated using expected cash flows, based on engineering and environmental reports prepared by third party industry specialists, discounted at a pre-tax rate specific to the liability. The capitalized amount is amortized on the same basis as the related asset. The liability is adjusted for the accretion of the discounted obligation and any changes in the amount or timing of the underlying future cash flows. Significant judgements and estimates are involved in forming expectations of the amounts and timing of future closure and reclamation cash flows.

Changes in closure and reclamation estimates are accounted for as a change in the corresponding capitalized cost.

Costs of rehabilitation projects for which a provision has been recorded are recorded directly against the provision as incurred, most of which are incurred at the end of the life of mine.

As at December 31, 2015, the Company has no material restoration, rehabilitation and environmental costs as the disturbance to date is minimal.

2. SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Loss per share

The Company uses the treasury stock method of calculating diluted per share amounts whereby any proceeds from the exercise of stock options or other dilutive instruments are assumed to be used to purchase common shares at the average market price during the period. The assumed conversion of outstanding common share options and warrants has an anti-dilutive impact in 2015 and 2014. Basic loss per share is calculated using the weighted-average number of shares outstanding during the period.

Share capital

The proceeds from the exercise of stock options, warrants and escrow shares are recorded as share capital in the amount for which the option, warrant or escrow share enabled the holder to purchase a share in the Company.

Commissions paid to underwriters, and other related share issue costs, such as legal, auditing, and printing, on the issue of the Company's shares are charged directly to share capital.

The Company has adopted a residual value method with respect to the measurement of shares and warrants issued as private placement units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component.

The fair value of the common shares issued in the private placements is considered to be the more easily measurable component and the common share are valued at their fair value, as determined by the closing quoted bid price on the announcement date. The balance, if any, is allocated to the attached warrants. Any fair value attributed to the warrants is recorded as reserves.

Income taxes

The Company uses the balance sheet method of accounting for income taxes. Under the balance sheet method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets also result from unused loss carry forwards, resource related pools and other deductions. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Share-based payments

The Company accounts for stock options granted to directors, officers, employees and non-employees at fair value. Accordingly, the fair value of the options at the date of the grant is determined using the Black-Scholes option pricing model and stock-based compensation is recorded and charged to operations, with an offsetting credit to the share-based payment reserve, over the vesting periods. The fair value of stock options granted to non-employees is re-measured at the earlier of each financial reporting or vesting date, and any adjustment is charged or credited to operations upon re-measurement. The number of shares and options expected to vest is reviewed and adjusted at the end of each reporting period such that the amount recognized for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest.

The expected price volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information.

2. SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Critical accounting estimates and judgments

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to the determination that the Company will continue as a going concern for the next year.

Impairment of long-lived assets

Management evaluates non-current assets at least annually for indicators that carrying value is impaired and may not be recoverable. When indicators of impairment are present the recoverable amount of an asset is evaluated at the level of a cash generating unit (CGU), the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets, where the recoverable amount of a CGU is the greater of the CGU's fair value less costs to sell and its value in use. An impairment loss is recognized in income to the extent that the carrying amount exceeds the recoverable amount.

Exploration tax credits

The Company recognizes exploration tax credit amounts when the Company's application is approved by the taxation authorities or when the amount to be received can be reasonably estimated and collection is reasonably assured. The amount of the exploration tax credits reduces the Company's deferred exploration costs through a credit to recoveries.

Flow-through shares

Canadian Income Tax legislation permits an enterprise to issue securities referred to as flow-through shares, whereby the investor can claim the tax deductions arising from the renunciation of the related resource expenditures. The Company accounts for flow-through shares whereby the premium paid for the flow through shares in excess of the market value of the shares without flow-through features at the time of issue is credited to other liabilities and included in profit or loss at the same time the qualifying expenditures are made.

Cash and cash equivalents

Cash and cash equivalents include cash in accounts and securities that on acquisition are convertible to cash within three months. These investments are highly liquid marketable securities.

New standards amendments and interpretations to existing standards not yet effective

Effective for annual reporting periods beginning on or after January 1, 2016

- IFRS 9, Financial Instruments
- IAS 1, Presentation of Financial Statements

The Company has not early adopted these new and amended standards and is currently assessing the impact that these standards will have on the Company's financial statements.

3. CASH AND CASH EQUIVALENTS

	December 31, 2015 $	**September 30, 2015 $**
Canadian chartered bank		
- Deposits	2,935	29,494
- Subscriptions received	149,432	-
	152,367	**29,494**

4. RECEIVABLES AND PREPAIDS

	December 31, 2015 $	**September 30, 2015 $**
GST/HST receivable	4,411	2,472
Interest receivable	239	232
Prepaid insurance	45,333	2,447
	49,983	**5,151**

5. EQUIPMENT

	Computer $	Office Equipment $	Total $
Cost			
As at September 30, 2014	44,325	49,020	93,345
Additions during the period	-	-	-
As at September 30, 2015	44,325	49,020	93,345
Additions during the year	-	-	-
As at December 31, 2015	**44,325**	**49,020**	**93,345**
Accumulated depreciation			
As at September 30, 2014	42,751	49,020	91,771
Amortization during the year	472	-	472
As at September 30, 2015	43,223	49,020	92,243
Amortization during the year	83	-	83
As at December 31, 2015	**43,306**	**49,020**	**92,326**
Net book value			
As at September 30, 2014	1,574	-	1,574
As at September 30, 2015	1,102	-	1,102
As at December 31, 2015	**1,019**	**-**	**1,019**

6. EXPLORATION AND EVALUATION ASSETS

Mt. Mervyn Property
Yukon Territory, Canada

In April 2011, the Company entered into an option agreement to acquire a 100% interest in the Mt. Mervyn gold property. The Mt. Mervyn property is located in the Mayo Mining District of central Yukon and is comprised of 314 unpatented mining claims.

During the year ended September 30, 2014, due to the market conditions, which led to the inability to finance the property, the Company wrote-down the property to a nominal amount of $1.

7. ACCOUNTS PAYABLE AND ACCRUED LIABLITIES

	December 31, 2015 **$**	**September 30, 2015** **$**
Trade accounts payable	166,201	53,972
Accrued liabilities	34,911	30,282
Due to related parties	156,449	133,234
	357,560	**217,488**

8. RELATED PARTY TRANSACTIONS

During the three months ended December 31, 2015, the Company paid or accrued $37,500 (December 31, 2014 - $72,582) to directors and officers or companies controlled by directors and officers of the Company, for management, accounting, and directors fees incurred by the Company. No incentive stock options were granted during the period. Included in accounts payable are directors' and officer's fees payable of $155,416 (September 30, 2015 - $69,927), which are non-interest bearing, unsecured, and payable on demand. Fair value cannot be reliably determined. Subsequent to the period, the amount payable to related parties was settled for shares with a value of $0.15 per share (Please refer to Note 12 – Subsequent Events).

Related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

9. SHARE CAPITAL

a) Authorized: Unlimited number of common shares

b) Issued and outstanding:

During the three months ended December 31, 2015, the Company did not issue any common shares.

In the previous year end, the TSX Venture Exchange approved the consolidation of the Company's share capital on the basis of every three (3) shares of the Company being consolidated to one share effective June 17, 2015. The Company currently has 3,889,113 shares issued and outstanding.

During the current period, the Company received subscriptions for a total of $149,433 (996,220 units @ $0.15) related to the private placement of $1,000,000 in conjunction with the acquisition of BSS. Subsequent to the period, the Company closed a non-brokered financing of 6,677,413 units ('Unit") for gross proceeds of $1,001,612. Please refer to Note 12 – Subsequent Events for details of other shares issued.

9. **SHARE CAPITAL** *(continued)*

c) Stock options:

The continuity of share purchase options (post-consolidation) is as follows:

Expiry Date	Exercise Price	30-Sep-15	Granted	Exercised	Expired/ Cancelled	31-Dec-15
14-Feb-16	6.00	20,000	-	-	-	20,000
14-Feb-16	2.25	6,667	-	-	-	6,667
14-Feb-16	1.50	23,331	-	-	-	23,331
14-Feb-16	0.165	6,666	-	-	-	6,666
21-Apr-16	6.00	51,001	-	-	-	51,001
11-Jul-16	6.00	6,667	-	-	-	6,667
12-Jan-17	2.25	3,333	-	-	-	3,333
20-Mar-17	2.25	11,666	-	-	-	11,666
23-May-17	1.50	39,001	-	-	-	39,001
14-Dec-17	0.50	23,334	-	-	-	23,334
15-May-18	0.50	32,333	-	-	-	32,333
23-Jul-19	0.165	26,000	-	-	-	26,000
		249,999	-	-	-	249,999
Weighted average exercise price		$ 2.79	-	-	-	$ 2.79

Expiry Date	Exercise Price	30-Sep-14	Granted	Exercised	Expired/ Cancelled	31-Dec-14
15-Oct-14	2.25	3,333	-	-	(3,333)	-
10-Jun-15	0.50	26,667	-	-	-	26,667
28-Jul-15	0.50	23,667	-	-	-	23,667
21-Sep-15	0.75	3,333	-	-	-	3,333
21-Apr-16	2.00	81,000	-	-	-	81,000
11-Jul-16	2.00	6,667	-	-	-	6,667
12-Jan-17	0.75	3,333	-	-	-	3,333
20-Mar-17	0.75	25,000	-	-	-	25,000
23-May-17	0.50	52,333	-	-	-	52,333
14-Dec-17	0.50	36,667	-	-	-	36,667
15-May-18	0.50	52,333	-	-	-	52,333
23-Jul-19	0.055	39,333	-	-	-	39,333
		353,667	-	-	(3,333)	350,333
Weighted average exercise price		$ 2.54	-	-	$ 2.25	$ 2.57

During the three months ended December 31, 2015, the Company did not grant any employee stock options.

In connection with the acquisition of BSS, all incentive stock options were cancelled and the company allocated 2,000,000 incentive stock options for distribution to directors, officers, employees and certain service providers. The incentive stock options have an exercise price of $0.15 per share for a period of five years. Once granted, the options will be subject to a four month hold period from the date of issuance. Please refer to Note 12 – Subsequent Events.

9. **SHARE CAPITAL** *(continued)*

d) Share purchase warrants

There were no outstanding share purchase warrants as at the three months ended December 31, 2015.

In connection with the acquisition of BSS, the Company granted the following warrants:

- 6,677,413 finance warrants exercisable for a period of two years at $0.25 in the first year and at $0.35 thereafter. In the event that the closing price of the Company's Shares on the CSE is equal to greater than $0.50 per share for 20 consecutive trading days at any time following four months after the date of closing the Acquisition, the Company may reduce the remaining exercise period of the Finance Warrants to not less than 30 days following the date of such notice;
- 220,186 broker warrants exercisable at $0.15 for a period of two years;
- 10,000,000 acquisition warrants to the shareholders of BSS on a pro-rata basis exercisable at $0.15 per share for a period of three years.

e) Share-based payment reserve

September 30, 2014	$	3,919,385
Fair-value of stock options granted		-
September 30, 2015	$	3,919,385
Fair-value of stock options granted		-
December 31, 2015	**$**	**3,919,385**

10. **NON CASH TRANSACATIONS**

The following non-cash transactions were recorded:

		December 31, 2015		**December 31, 2014**
Financing activities				
Shares issued for exploration and evaluation assets	$	-	$	-

11. **CAPITAL MANAGEMENT AND FINANCIAL INSTRUMENTS**

(a) Capital Management Objectives

The Company's primary objective when managing capital is to safeguard the Company's ability to continue as a going concern, so that it can continue to provide returns for shareholders, and to have sufficient liquidity available to fund suitable business opportunities as they arise.

The Company considers the components of shareholders' equity, as well as its cash and equivalents as capital. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk of characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue equity, sell assets, or return capital to shareholders as well as issue or repay debt. The Board of Directors has not established quantitative capital structure criteria management, but will review on a regular basis the capital structure of the Company to ensure its appropriateness to the stage of development of the business.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the company, is reasonable.

11. **CAPITAL MANAGEMENT AND FINANCIAL INSTRUMENTS** *(continued)*

(a) Capital Management Objectives *(continued)*

In order to facilitate the management of its capital requirements, the Company prepares annual expenditure budgets, which are updated as necessary and are reviewed and approved by the Company's Board of Directors. In addition, the Company may issue new equity, incur additional debt, or dispose of certain assets. When applicable, the Company's investment policy is to hold cash in interest bearing accounts at high credit quality financial institutions to maximize liquidity. In order to maximize ongoing development efforts, the Company does not pay dividends. The Company expects to continue to raise funds, from time to time, to continue meeting its capital management objectives.

There were no changes in the Company's approach to capital management during the period ended December 31, 2015.

(b) Carrying Amounts and Fair Values of Financial Instruments

The fair value of a financial instrument is the price at which a party would accept the rights and/or obligations of the financial instruments from an independent third party. Given the varying influencing factors, the reported fair values are only indicators of the prices that may actually be realized for these financial instruments.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
Level 3—Inputs that are not based on observable market data

The following table illustrates the classification of the Company's financial instruments within the fair value hierarchy as at December 31, 2015.

	Level 1	**Level 2**	**Level 3**	**Total**
Cash	$ 152,367*	$ –	$ –	$ 152,367
Security deposits	$ 5,750	$ –	$ –	$ 5,750

* Includes $149,433 in shares subscribed for that have not been issued. Please refer to Note 12 – Subsequent Events.

(c) Carrying Amounts and Fair Values of Financial Instruments (continued)

The following table illustrates the classification of the Company's financial instruments within the fair value hierarchy as at September 30, 2015.

	Level 1	**Level 2**	**Level 3**	**Total**
Cash	$ 29,494	$ –	$ –	$ 29,494
Security deposits	$ 5,750	$ –	$ –	$ 5,750

12. SUBSEQUENT EVENTS

Subsequent to the period, the Company closed the acquisition of BSS Life Sciences "BSS"). In connection with the closing, the Company:

- issued 21,500,000 common shares ("Acquisition shares") to the shareholders of BSS on a pro-rata basis. Of these, 11,500,000 shares are subject to escrow, to be released over three years (10% on the closing date and an additional 15% every six months thereafter);
- issued 10,000,000 warrants ("Acquisition Warrants") to the holders of warrants of BSS on a pro-rata basis; each Acquisition Warrant exercisable at $0.15 per share for three years;
- issued 5,000,000 performance shares to certain shareholders of BSS. These shares are subject to escrow, and to be released upon the successful conclusion of a beta prototype pertaining to BSS Life's technology which satisfactorily demonstrates the commercial viability of products based on such technology;
- changed its name from Expedition Mining Inc. to Imagin Medical Inc. and changed its trading symbol to "IME";
- closed a non-brokered financing of 6,677,413 units ("Unit") at $0.15 per Unit for gross proceeds of $1,001,612. Each Unit is comprised of one common share ("Shares") and one share purchase warrant ("Finance Warrant"). Each Finance Warrant is exercisable for a period of two years at $0.25 in the first 12 months and at $0.35 thereafter, provided that in the event the closing price of the Company's Shares on the CSE is equal to greater than $0.50 per share for 20 consecutive trading days at any time following four months after the date of closing the Acquisition, the Company may reduce the remaining exercise period of the Finance Warrants to not less than 30 days following the date of such notice. The private placement securities are subject to a four month hold period from the date of issuance. The Company paid a total of $37,528 and issued a total of 220,186 brokers' warrants @ $0.15 per warrant expiring 2 years.
- completed a shares-for-debt transaction to settle $155,416.27 of past debt owed to former directors and officers of EXU, by the issuance of 1,036,108 shares at a deemed price of $0.15 per share. These shares are subject to a four month hold period from the date of issuance;
- granted 2,000,000 incentive stock options, exercisable at $0.15 per share for a period of five years. The options are subject to a four month hold period from the date of grant; and
- changed its business from that of a mining exploration company to a medical technology company.

After the closing of the acquisition, the Company currently has 38,102,634 issued and outstanding Shares; 10,000,000 Acquisition Warrants; 6,677,413 Finance Warrants; 220,186 Broker Warrants; and 2,000,000 incentive stock options. The Company will continue to hold open its private placement, and as such additional Units may be sold prior to the resumption of trading of its shares.